RNS Number : 1754B
Tristel PLC
20 April 2026
Tristel plc
("Tristel" or the "Company")
Holding(s) in Company
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it was notified on 17 April 2026 that, as of 16 April 2026, Artemis Investment Management LLP, holds, 3.00216 per cent. of the Company's issued share capital.
For further information please contact:
Tristel plc
Via Walbrook PR
Matt Sassone, Chief Executive Officer
www.investors.tristel.com
Anna Wasyl, Chief Financial Officer
Walbrook PR Ltd
Tel: 020 7933 8780 ortristel@walbrookpr.com
Paul McManus / Lianne Applegarth / Anna Dunphy
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001
Cavendish Capital Markets Ltd
Tel: 020 7220 0500
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLAKKBBNBKDQQB
